Results 121 to 130 of about 29,778 (296)

Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease.

open access: yes, 2014
Background: Elevated plasma B-type natriuretic peptide (BNP) levels and their association with heart failure have been reported in subjects with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Oga, T   +5 more
core   +1 more source

The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 980-997, April 2025.
Abstract Heart failure (HF) creates a considerable clinical, humanistic and economic burden on patients and caregivers as well as on healthcare systems. To attenuate the significant burden of HF, there is a need for enhanced management of patients with HF.
Javed Butler   +8 more
wiley   +1 more source

Determination of B-type natriuretic peptides: Clinical and analytical quality [PDF]

open access: yesJournal of Medical Biochemistry, 2007
B-type natriuretic peptide (BNP), a neurohormone synthesized in the cardiac ventricles, is released as preproBNP and then enzymatically cleaved to the N-terminal-proBNP (NT-proBNP) and BNP upon ventricular myocite stretch.
Kovačević Radmila, Mirić Milutin
doaj  

The outcomes of electronic personal health records in patients with heart failure or coronary artery disease

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1464-1468, April 2025.
Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka   +16 more
wiley   +1 more source

“Rebranding” Natriuretic Peptides [PDF]

open access: yesClinical Chemistry, 2020
James L, Januzzi, Nasrien E, Ibrahim
openaire   +2 more sources

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

Distinct submembrane localisation compartmentalises cardiac NPR1 and NPR2 signalling to cGMP

open access: yesNature Communications, 2018
Natriuretic peptides (NPs) are important hormones that regulate cardiovascular physiology by increasing cGMP levels in cardiomyocytes. Here the authors use scanning ion conductance microscopy and a cGMP FRET sensor to identify a differential localisation
Hariharan Subramanian   +5 more
doaj   +1 more source

Clinical Significance of natriuretic peptides

open access: yes, 2022
Natriuretic peptides are widely known for their protective effects against the development of metabolic syndrome and cardiovascular disease. The important role of determining the levels of natriuretic peptides in the diagnosis, assessment of severity ...
Rogachova, Tetiana   +2 more
core  

Natriuretic peptides and their usefulness in clinical practise

open access: yes, 2020
Natriuretic peptides are peptic hormones produced by atrial and ventricular myocytes, and by endothelium of blood vessels, that take part in homeostatic control of water and sodium levels, but also potassium transport, lipolysis in adipocytes and blood ...
Romaniuk, Małgorzata   +11 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy